The inventors have discovered that certain peptide fragment derived from the major allergen of birch pollen species is useful as a de-sense crystallized individual against those allergens. Birch Bet v2, Bet v1, Bet v3 , Bet v4, Bet v6, Bet v7: a peptide derived from the piece (generic name Betulaceae) is particularly useful. Peptide of the invention is a peptide - the main histocompatibility complex interactions (peptide-MHC interactions) and the main histocompatibility complex class Ⅱ binding assay (MHC class-Ⅱ binding assays) and through the double Rico analysis to predict the main histocompatibility complex class ⅱ- binding T cell antigen were selected as the determination area. Additional antigen determining region was identified as homologous relationship. Difficulties related to the ride feeling angry attempts based on peptide immunization lies in how to choose the appropriate size and region of the allergen. The choice of peptide size is important. If the peptide is too small, the vaccine would not be effective naeneunde lead the immune response. The antigenic peptide is too large or risk the whole cause adverse reactions, such as reactions to individuals and civil exceed introduced if it can be fatal. Polypeptide of the present invention are small enough to not own an important eumyeonseo quaternary structure that enables it to maintain the structure of the antigen binding sites in the immunoglobulin E determine the whole molecule were selected to maintain T cell specificity. Therefore, the polypeptide of the invention therefore do not induce significant histamine release not induce significant crosslinking of adjacent specific immune cells such as mast cells and hoyeomgu immunoglobulin E molecule. The advantages of the present invention is the ability of a peptide that can attack comprehensively the main histocompatibility complex (MHC) molecule. T cell receptor specificity is highly variable in the surface. Variability is generated with the ant
